These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 27838913)

  • 1. Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM).
    Willis M; Johansen P; Nilsson A; Asseburg C
    Pharmacoeconomics; 2017 Mar; 35(3):375-396. PubMed ID: 27838913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM).
    Willis M; Asseburg C; He J
    J Med Econ; 2013 Aug; 16(8):1007-21. PubMed ID: 23718682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions.
    Lopes S; Johansen P; Lamotte M; McEwan P; Olivieri AV; Foos V
    Pharmacoeconomics; 2020 Oct; 38(10):1123-1133. PubMed ID: 32656686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the IHE Cohort Model of Type 2 Diabetes and the impact of choice of macrovascular risk equations.
    Lundqvist A; Steen Carlsson K; Johansen P; Andersson E; Willis M
    PLoS One; 2014; 9(10):e110235. PubMed ID: 25310196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Prime Diabetes Model: Novel Methods for Estimating Long-Term Clinical and Cost Outcomes in Type 1 Diabetes Mellitus.
    Valentine WJ; Pollock RF; Saunders R; Bae J; Norrbacka K; Boye K
    Value Health; 2017; 20(7):985-991. PubMed ID: 28712629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of a Health Policy Model of Type 2 diabetes in Chinese setting.
    Wu B; Ma J; Zhang S; Zhou L; Wu H
    J Comp Eff Res; 2018 Aug; 7(8):749-763. PubMed ID: 30132342
    [No Abstract]   [Full Text] [Related]  

  • 7. Validation of the CORE Diabetes Model against epidemiological and clinical studies.
    Palmer AJ; Roze S; Valentine WJ; Minshall ME; Foos V; Lurati FM; Lammert M; Spinas GA
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S27-40. PubMed ID: 15324514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of patient-reported and economic outcomes: value to stakeholders in the decision-making process in patients with type 2 diabetes mellitus.
    Vieta A; Badia X; Sacristán JA
    Clin Ther; 2011 Sep; 33(9):1225-45. PubMed ID: 21856000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of the IMS CORE Diabetes Model.
    McEwan P; Foos V; Palmer JL; Lamotte M; Lloyd A; Grant D
    Value Health; 2014 Sep; 17(6):714-24. PubMed ID: 25236995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methods applied in cost-effectiveness models for treatment strategies in type 2 diabetes mellitus and their use in Health Technology Assessments: a systematic review of the literature from 2008 to 2013.
    Charokopou M; Sabater FJ; Townsend R; Roudaut M; McEwan P; Verheggen BG
    Curr Med Res Opin; 2016; 32(2):207-18. PubMed ID: 26473650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
    Palmer AJ; Roze S; Valentine WJ; Minshall ME; Foos V; Lurati FM; Lammert M; Spinas GA
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S5-26. PubMed ID: 15324513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7.
    Eddy DM; Hollingworth W; Caro JJ; Tsevat J; McDonald KM; Wong JB;
    Value Health; 2012; 15(6):843-50. PubMed ID: 22999134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes.
    van Giessen A; Boonman-de Winter LJ; Rutten FH; Cramer MJ; Landman MJ; Liem AH; Hoes AW; Koffijberg H
    Cardiovasc Diabetol; 2016 Mar; 15():48. PubMed ID: 27001409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of the economic and health impact of complications of type 2 diabetes mellitus in the autonomous community of Madrid (Spain).
    Arrieta F; Rubio-Terrés C; Rubio-Rodríguez D; Magaña A; Piñera M; Iglesias P; Nogales P; Calañas A; Novella B; Botella-Carretero JI; Debán C; Zamarrón I; Mora G; Balsa JA; Vázquez C;
    Endocrinol Nutr; 2014 Apr; 61(4):193-201. PubMed ID: 24440211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
    Viriato D; Calado F; Gruenberger JB; Ong SH; Carvalho D; Silva-Nunes J; Johal S; Viana R
    J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective Treatment Recommendations for Type 2 Diabetes Management Using Reinforcement Learning: Treatment Recommendation Model Development and Validation.
    Sun X; Bee YM; Lam SW; Liu Z; Zhao W; Chia SY; Abdul Kadir H; Wu JT; Ang BY; Liu N; Lei Z; Xu Z; Zhao T; Hu G; Xie G
    J Med Internet Res; 2021 Jul; 23(7):e27858. PubMed ID: 34292166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM.
    Willis M; Fridhammar A; Gundgaard J; Nilsson A; Johansen P
    Pharmacoeconomics; 2020 Sep; 38(9):953-969. PubMed ID: 32399797
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.